A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Talazoparib (Primary) ; Irinotecan; Temozolomide
- Indications Solid tumours
- Focus Adverse reactions
- 06 Feb 2018 Planned End Date changed from 31 Mar 2020 to 1 Mar 2020.
- 06 Feb 2018 Planned primary completion date changed from 31 Oct 2019 to 1 Oct 2019.
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology